

Vivos Therapeutics, Inc.

Q2 FY24 revenue up 19% yoy. New sleep medicine marketing strategy very promising. Raising price target to \$6.60 (from \$6.40). Reiterate BUY

COMPANY UPDATE

Q2 revenues beat on better pricing: On August 14, VVOS reported Q2 (ending June) FY24 results. Revenue was \$4.1 million, up 19% yoy and qoq. This compares to our estimate of \$3.6 million and consensus estimate of \$3.8 million. Reduced discounting was a key driver of higher-than-expected revenues, as new FDA clearances have allowed the company to charge fuller prices. Pro forma EPS was \$(0.60), versus ours and consensus estimate of \$(1.05).

Operating expenses down 22% yoy: Operating expenses in Q2 FY24 were \$4.6 million (down 31% yoy), versus our estimate of \$5.4 million. The yoy decline in operating expenses reflects the company's ongoing focus on cost control, with headcount reduced from a high of 180 to 100, and cost ROI discipline introduced across the company.

Raising estimates: We are raising our FY24 EPS estimates to (3.13) from (4.14) on higher revenue expectations and lower cost run-rates. We are raising our FY24 revenue estimate to (3.63) million from (14.9) million. We are raising our FY25 estimate to (2.47), from (3.02) previously, on revenues of (3.95) and million, versus (3.95) and (2.29) on revenues of (3.61) million and (3.91) million for FY24 and FY25, respectively.

New medical sleep specialist marketing strategy taking shape: Last quarter, the company announced a new partnership initiative involving 'large medical groups, hospitals, and sleep testing centers'. The idea is to gain direct access to OSA patients who are likely to be interested in a CPAP alternative via affiliation with physicians, as opposed to the company's traditional channel: partnering with dentists who then recommend Vivos products and share revenues with the company. The first such partnership, with a large sleep center in Colorado, is already yielding positive results, and the company hopes that it will mark the beginning of a new growth phase for Vivos. Talks are underway to expand this model to 6 other centers.

Marketing pilot reveals 80% conversion rate for Vivos appliances versus CPAP: In June Vivos announced positive results from a 7-month, multi-site marketing pilot testing the core assumptions behind Vivos' new medical sleep specialist distribution model. 79% of newly diagnosed adult OSA patients chose Vivos' oral appliance therapy over either CPAP machines or choosing to do nothing. This suggests that when made aware of the non-invasive Vivos option, most patients will choose Vivos. The company estimates that for every 100 new patients introduced by sleep specialists, Vivos can realize \$8 million in annual revenues. For perspective, the US has 2,500 accredited sleep testing centers, with 100,000 new OSA patients diagnosed each month.

Private Equity investment extends cash runway: Following a \$7.5 million investment by Seneca Partners in June, Vivos had \$6.9 million in cash exiting Q2. Given the company's affirmed target of reaching cashflow breakeven by Q1 of FY25, the risk of further dilutive financing is falling.

Revenue bottoming provides stock catalyst: We are maintaining our BUY rating and raising our 12-month price target to \$6.60 from \$6.40, based on an NPV analysis. This represents 180% upside from the current share price. Despite hurdles the company has faced, we believe the company's multi-billion-dollar market potential and favorable product positioning present high rewards for the risks. Revenues appear to be re-accelerating, providing a near-term stock catalyst.

Company Description

Based in Littleton, Colorado, Vivos is a medical technology company focused on innovative solutions for obstructive sleep apnea (OSA) and snoring.

United States Healthcare

August 20, 2024

Lucas Ward (561) 427-7788 lward@ascendiant.com

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$1.91-48.79
Shares Outstanding (million):	3.2
Market cap (\$million):	\$7.5
EV (\$million):	\$0.6
Debt (\$million):	\$0
Cash (\$million):	\$6.9
Avg. Daily Trading Vol. (\$million):	\$0.125
Float (million shares):	2.5
Short Interest (million shares):	0.06
Dividend, annual (yield):	NA

Revenues (US\$ million)

	<u>2024E</u> (Cur.)	<u>2024E</u> (Old.)	<u>2025E</u> (Cur.)	2025E <u>(Old.)</u>
Q1 Mar	3.4A	3.5E	4.0E	
Q2 Jun	4.1A	3.6E	4.8E	4.2E
Q3 Sep	4.3E	3.8E	5.1E	4.5E
Q4 Dec	<u>4.5E</u>	<u>4.1E</u>	<u>5.3E</u>	<u>4.8E</u>
Total	16.3E	14.9E	19.2E	17.6E
EV/Rev	NM		NM	

Earnings per Share (pro forma)

	<u>2024E</u> (Cur.)	<u>2024E</u> (Old.)	<u>2025E</u> (Cur.)	2025E (Old.)
Q1 Mar	(1.63)A	<u></u>	(0.77)E	(0.85)E
Q2 Jun	(0.60)A	(1.05)E	(0.62)E	(0.78)E
Q3 Sep	(0.70)E	(0.96)E	(0.58)E	(0.74)E
Q4 Dec	<u>(0.67)E</u>	<u>(0.87)E</u>	<u>(0.51)E</u>	<u>(0.65)E</u>
Total	\$(3.13)E	\$(4.14)E	\$(2.47)E	\$(3.02)E
PE	NM		NM	

* Reflects a 1:25 reverse stock split in October 2023

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 13.

Rating: BUY

Ticker:	VVOS	
Price:	\$2.33	
Target:	\$6.60	
Fro	m \$6.40	



Exhibit 1: Vivos Therapeutics Inc. Sleep Apnea Technology



Vivos brings to market breakthrough technology in both diagnosis and treatment of dentofacial abnormalities and/ or mild to moderate OSA and snoring.



Source: Company Documents

Exhibit 2: The Vivos Method



is our multidisciplinary treatment protocol that uses

nonsurgical | noninvasive | cost-effective ORAL APPLIANCE TECHNOLOGY

prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild to moderate OSA and snoring.



Vivos



Exhibit 3: Sleep Apnea Comorbidities




Exhibit 4: Vivos Therapeutics, Inc. Dentist Customer Stats

Over 1,450 Dentists Trained

Dentists have hundreds of existing patients of all ages who are suffering from OSA

- Typical VIP Dentist has well over 400 existing patients who may suffer from (undiagnosed) OSA
- Represents a multi-million-dollar revenue opportunity for dental practices

\$9,000 Typical Case Fee to Patient

(\$3,000) Estimated Total Cost to DDS

\$6,000 Estimated Total Margin DDS







Exhibit 5: Vivos Therapeutics, Inc. Competitive Strengths



Our Competitive Strengths

- FDA registrations and clearances since 2009
- Only appliance of its kind eligible for Medicare reimbursement
- Significant barriers to entry
- Vivos Method Insurance reimbursement
- · Body of published research and strong patient outcomes
- First mover advantage in Sleep Dentistry Space and Differentiated Products
- Established strategic alliances within the medical and dental community
- Intellectual property portfolio and research and development capabilities
- Extensive Training and Support Systems
- Compelling economics and value-added services to VIPs at all levels of the product and service delivery chain
- Marketplace acceptance approximately 25,000 patients treated – over 1,450 Vivos-trained independent dentists



Source: Company Documents

Exhibit 6: Vivos Therapeutics, Inc. Oral Appliances







Exhibit 7: 73-Year-Old Male Airway CBT Scan Before and After Vivos Treatment

73-Year-Old Male - 17 Months Treatment



Source: Company Documents


Exhibit 8: 30-Year-Old Male Airway CBT Scan Before and After Vivos Treatment

30-Year-Old Male - 14 Months Treatment





Exhibit 9: Vivos Therapeutics, Inc. Revenue Model





Source: Company Documents



The Vivos Ecosystem The VIP Program

- Our Secondary source of revenue is our clinical training and practice support programs.
- Our program to train dentists and offer them other value-added services is called the
- Vivos Integrated Practice (VIP) program.
- The VIP program provides dentists with a strong economic incentive to provide this treatment and prescribe the Vivos Method, together with practice support services.







Exhibit 11: Illustrative Economics for Vivos Dentists



Illustrative Economics for a General Dentist

Number of Active Patients in Typical Dental Practice	Potential patients with OSA	Potential Additional Revenue for Dentist
1,250	375	\$3,375,000
1,500	450	\$4,050,000
1,750	525	\$4,725,000
2,000	600	\$5,400,000
2,250	675	\$6,075,000

Vivos[™]

Source: Company Documents

Exhibit 12: Sleep Apnea Competitive Landscape

Competitive Landscape

	Treatment Protocol	Target the Underlying Condition	Required Treatment Time to Resolve Symptoms	Overall Efficacy of Treatment	Pain Associated with Treatment	Potential Negative Side- Effects	Average Duration of Treatment/ Intervention	Duration of Benefits	Health Insurance Coverage	Health Insurance Coverage	Est. Average Treatment Cost
atment asive)	Vivos.	****	Potentially Immediate	****	Minor or None	Minor	12-24 Months	****	Yes	YES In Most Case	\$9,000
Non-Surgical Treatment Options (Non-Invasive)	СРАР	****	Potentially Immediate	****	Minor or None	Moderate	Lifetime	****	Yes	Yes	\$10,000/ 10 years Plus Consumables
Non-Sur Options	Oral Appliance Therapy	****	Potentially Immediate	****	Minor or None	Moderate	Lifetime	****	No	YES In Most Case	\$3,000 - \$8,000
s) ut	Inspire Medical®	*****	Potentially Immediate	****	In Some Cases	Major	Lifetime	****	No	YES In Most Case	\$30,000- \$40,000
Surgical Treatment Options (Invasive)	Uvulopalatopharygoplasty (UPPP Surgery)	****	Potentially Immediate	****	During Recovery	Major	Surgery + Healing Time	****	No	Yes	\$2,000 - \$10,000
Surg Opti	Maxillomandibular Advancement Surgery	****	Potentially Immediate	****	During Recovery	Major	Surgery + Healing Time	****	Yes	Yes	\$70,000





Exhibit 13: Vivos Therapeutics, Inc. Insurance Reimbursement





Exhibit 15: Vivos Therapeutics, Inc. Consensus Estimates

August 20, 2024		
	Rev	enue (million)
	2024E	2025E
1 Mar	3.4A	4.1E
2 Jun	3.8E	4.5E
3 Sep	4.3E	5.1E
4 Dec	4.5E	5.3E
tal	16.1E	19.1E

Note: Quarterly estimates may not add up to annual estimates due to variance in analyst reporting practices

Source: CapitalIQ, Ascendiant Capital Markets





* Reflects a 1:25 reverse stock split in October 2023

Source: https://bigcharts.marketwatch.com/



10% 10%

Financial Model

Vivos Therapeutics, Inc. Income Statement (\$ mils)	2021	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	FY-A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Product revenue	39%	52%	46%	46%	44%	46%	45%	49%	49%								
Service revenue	61%	48%	54%	54%	56%	54%	55%	118%	148%								
Product revenue	6.5	8.4	1.8	1.5	1.5	1.5	6.3	1.7	2.0								
Service revenue	10.4	7.6	2.1	1.8	1.8	1.8	7.5	1.7	2.1								
Total revenue	16.9	16.0	3.9	3.4	3.3	3.2	13.8	3.4	4.1	4.3	4.5	16.3	4.0	4.8	5.1	5.3	19.2
Total cost of goods sold	4.3	6.0	1.5	1.3	1.4	1.3	5.5	1.5	1.4	1.5	1.6	6.0	1.4	1.7	1.8	1.9	6.
Gross profit (loss)	12.6	10.0	2.3	2.1	1.9	1.9	8.3	1.9	2.7	2.8	2.9	10.3	2.6	3.1	3.3	3.5	12.5
Operating expenses																	
General and administrative	25.8	29.0	6.5	5.9	4.6	5.5	22.5	4.9	4.1	4.3	4.3	17.6	4.4	4.3	4.3	4.2	17.
Sales and marketing	5.6	5.3	0.6	0.6	0.6	0.6	2.5	0.7	0.3	0.6	0.6	2.2	0.6	0.7	0.7	0.7	2.
Depreciation and amortization	0.7	0.7	0.2	0.1	0.2	0.1	0.6	0.1	0.1	0.1	0.1	0.6	0.1	0.1	0.1	0.1	0. E
Other (3, 4)	0.9																
fotal operating expenses	33.0	35.1	7.3	6.6	5.4	6.2	25.6	5.7	4.6	5.1	5.1	20.4	5.1	5.1	5.2	5.1	20.
Loss from operations	(20.4)	(25.0)	(5.0)	(4.5)	(3.5)	(4.3)	(17.3)	(3.8)	(1.9)	(2.3)	(2.2)	(10.1)	(2.5)	(2.0)	(1.9)	(1.6)	(8.0
ther income (expense)																	
Excess warrant fair value			(6.5)			0.0	(6.5)					0.0					0.0
Change in fair value of warrant liability, net of issuar	ce costs o	of \$645K	9.6	(0.9)	1.6	(0.1)	10.2					0.0					0.0
Interest income (expense)	0.1	0.0	0.0				0.0					0.0					0.0
Other income (expense) (5)	(0.0)	<u>1.2</u>	<u>0,1</u>	(0.1)	(0.2)	0.2	(0.1)	<u>0.0</u>	<u>0.0</u>			0.0					0.0
ncome before taxes Taxes	(20.3) 0.0	(23.8)	(1.7)	(5.5)	(2.1) 0.0	(4.3) 0.0	(13.6) 0.0	(3.8)	(1.9) 0.0	(2.3) 0.0	(2.2)	(10.1) 0.0	(2.5)	(2.0)	(1.9)	(1.6)	(8.0
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
let loss	(20.3)	(23.8)	(1.7)	(5.5)	(2.1)	(4.3)	(13.6)	(3.8)	(1.9)	(2.3)	(2.2)	(10.1)	(2.5)	(2.0)	(1.9)	(1.6)	(8.0
Ionrecurring/noncash adjustments (1,2)	0.0 (20.3)	(23.8)	(1.7)	(5.5)	(2.4)	(4.2)	122.02	(3.8)	14.03	(2.3)	(2.2)	(10.1)	(2.0)	(2.0)	(1.0)	0.0	(8.0
let income (pro forma)	(20.3)	(23.6)	(1.7)	(5.5)	(2.1)	(4.3)	(13.6)	(3.6)	(1.9)	(2.5)	(2.2)	(10.1)	(2.5)	(2.0)	(1.9)	(1.6)	(8.0
BITDA	(21.1)	(25.7)	(5.2)	(4.7)	(3.6)	(4.4)	(17.9)	(3.9)	(2.1)	(2.3)	(2.2)	(10.1)	(2.5)	(2.0)	(1.9)	(1.6)	(8 .0
Weighted average common shares outstanding (6)	0.8	0.9	1.0	1.2	1.2	1.5	1.2	2.3	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
Shares, Diluted	0.8	0.9	1.0	1.2	1.2	1.5	1.2	2.3	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
PS Basic (pro forma)	(23.89)	(25.90)	(1.72)	(4.62)	(1.75)	(2.85)	(11.14)	(1.63)	(0.60)	(0.70)	(0.67)	(3.13)	(0.77)	(0.62)	(0.58)	(0.51)	(2.47
PS Diluted (pro forma)	(23.89)	(25.90)	(1.72)	(4.62)	(1.75)	(2.85)	(11.14)	(1.63)	(0.60) (0.60)	(0.70)	(0.67)	(3.13)	(0.77)	(0.62)	(0.58)	(0.51)	(2.47
1 Destand shades and a contract (DV10, 20)																	
1 Preferred stock accretion (FY18-20) 2 Warrant beneficial conversion feature (Q4 '20)																	
3 Litigation settlement (Q4 '20 opex)																	
4 Impairment charge (Q4 '21 opex)																	
5 PPP loan forgiveness Q1 '22																	
6 Reverse stock-split on Oct 26, 2023, 1:25																	
Margins																	
Gross margin	75%	63%	61%	62%	57%	60%	60%	57%	65%	65%	65%	63%	65%	65%	65%	65%	655
General and admin	153%	181%	169%	173%	139%	168%	163%	144%	102%	100%	96%	108%	109%	90%	85%	79%	909
Sales and marketing	33%	33%	16%	17%	19%	19%	18%	19%	8%	14%	14%	14%	14%	14%	14%	14%	149
Operating margin	-121%	-156%	-130%	-133%	-105%	-132%	-125%	-111%	-48%	-52%	-48%	-62%	-62%	-42%	-37%	-31%	-429
Tax rate, GAAP	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NN
Net margin	-120%	-149%	-44%	-163%	-63%	-131%	-98%	-110%	-48%	-52%	-48%	-62%	-62%	-42%	-37%	-31%	-429
Y/Y % change																	
Revenue	29%	-5%	6%	-19%	-22%	-18%	-14%	-11%	19%	30%	39%	18%	18%	18%	18%	18%	189
COGS	61%	40%	39%	-19%	-20%	-16%	-8%	-3%	8%	7%	20%	8%	-5%	19%	18%	18%	139
Gross Profit	21%	-21%	-8%	-19%	-24%	-19%	-17%	-17%	26%	47%	51%	25%	35%	17%	18%	18%	219
General and Admin	60%	-21%	2%	-24%	-31%	-13%	-17%	-25%	-30%	-6%	2%	-22%	-11%	4%	10%	2%	-35
Sales and marketing	140%	5%	5%	-65%	-42%	5%	5%	4%	-46%	-6%	5%	-11%	-14%	109%	18%	5%	22
Total operating expenses	47%	5%	-20%	-03%	-42%	-26%	-27%	-22%	-40%	-6%	-18%	-11%	-14%	109%	2%	376 0%	0
Operating Income	69%	23%	-20%	-31%	-32%	-26%	-27%	-22%	-57%	-8%	-18%	-20%	-11%	4%	-18%	-24%	-21
Operating Income Net income	13%	23%	-25%	-35%	-35% -61%	-29%	-51%	-24%	-57%	-35%	-50% -49%	-41%	-34%	4% 4%	-18%	-24%	-215
FPS	-32%			-21%		+ = / -		-5%						4%			
EF3	-32%	8%	-73%	1302%	583%	-57%	-57%	-5%	-87%	-60%	-77%	-72%	-53%	4%	-18%	-24%	-21%

Source: Company reports , Ascendiant Capital Markets estimates

21%

12%

12% 10% 10%

D&A as a % of PPE and Good will

10%

10%

10%

10%

10%

* Reflects a 1:25 reverse stock split in October 2023

10% 10% 10%

10%

10%



Vivos Therapeutics, Inc.

Balance Sheet (\$ mils)	Dec-21	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
Fiscal Year End: December 31	Q4A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Current assets														
Cash	24.0	3.5	7.0	3.9	1.0	1.6	2.6	6.9	4.7	2.7	0.3	(1.7)	(3.4)	(5.0)
Accounts receivable, net	1.2	0.5	0.3	0.3	0.2	0.2	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Current portion of note receivable - related part	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred offering costs		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tenant improvement allowance receivable	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other assets	1.6	1.4	1.3	1.1	0.8	0.6	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total current assets	27.3	5.4	8.7	5.3	2.0	2.5	3.6	7.9	5.7	3.6	1.2	(0.7)	(2.5)	(4.0)
Goodwill	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
Property and equipment, net	2.8	3.1	3.2	3.3	3.3	3.3	3.3	3.3	3.2	3.1	3.1	3.1	3.1	3.1
Operating lease right-of-use asset		1.7	1.6	1.5	1.5	1.4	1.3	1.2	1.2	1.2	1,2	1.2	1.2	1.2
Intangible assets, net	0.3	0.3	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Note receivable, net - related party	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deposits	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Total assets	33.7	13.7	17.1	13.7	10.3	10.7	11.8	15.8	13.6	11.4	9.0	7.1	5.3	3.8
Liabilities and Stockholders' Equity														
Current liabilities														
Accounts payable	0.9	1.4	1.5	1.3	1.5	2.1	2.5	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Payable to related party for redemption of Serie	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liability	0.0	0.0	1.3	2.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued expenses	2.9	1.9	1.9	1.9	1.9	2.3	2.5	2.2	2.2	2.2	2.2	2.2	2.2	2.2
Current portion of contract liabilities	2.4	2.9	2.6	2.4	2.4	2.1	2.4	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Current portion of long-term debt	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current portion of deffered rent	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current portion of operating lease liability	0.0	0.4	0.0	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	0.0	0.4	0.4	0.4		0.2	0.2	0.2	0.2	0.2	0.5	0.2	0.2	0.5
Other current liabilities Total current liabilities	7.5	6.8	8.0	8.4	0.3	7.3	8.1	6.6	6.6	0.2 6.6	0.2 6.6	6.6	6.6	6.6
Contract liabilities, net of current portion	7.5	0.1	0.3	0.3	0.2	0.3	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4
		0.1	0.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
Employee retention credit liability		2.0							1.2					
Operating lease liability, net of current portion		2.0	1.9	1.8	1.6	1.5	1.4	1.3		1.3	1.3	1.3	1.3	1.3
Long-term debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred rent	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Lease incentive liability, net of current portion									0.0	414				
Total liabilities	8.2	8.9	10.1	11.6	10.3	10.3	11.2	9.5	9.5	9.5	9.5	9.5	9.5	9.5
Commitments and Contingencies	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Stockholders' Equity														
Preferred stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	81.2	84.3	88.2	88.8	88.8	93.5	97.4	105.1	105.1	105.1	105.1	105.1	105.1	105.1
Accumulated deficit	(55.6)	(79.5)	(81.2)	(86.7)	(88.8)	(93.1)	(96.8)	(98.7)	(101.0)	(103.2)	(105.6)	(107.6)	(109.5)	(111.1)
Total stockholders' equity	25.5	4.8	7.0	2.1	0.0	0.4	0.6	6.3	4.1	1.9	(0.5)	(2.6)	(4.4)	(6.0)
Total liabilities and stockholders' equity	33.7	13.7	17.1	13.7	10.3	10.7	11.8	15.8	13.6	11.4	8.9	6.9	5.1	3.5

Balance Sheet Drivers

	Dec-21	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
	Q4A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)														
Book Value per Share (diluted)	30.07	5.22	7.06	1.76	0.04	0.34	0.25	1.97	1.27	0.60	(0.17)	(0,79)	(1.37)	(1.87)
Cash per Share (diluted)	30.15	5.40	8.47	4.19	1.47	1.85	1.34	2.31	1.64	1.00	0.25	(0,34)	(0.89)	(1.37)
Net cash per Share (diluted)	26.80	3.82	7.11	3.29	0.83	1.35	1.13	2.14	1.47	0.83	0.08	(0.51)	(1.06)	(1.54)

Source: Company reports, Ascendiant Capital Markets estimates



Vivos Therapeutics, Inc.


Cash Flow Statement (\$ mils)	2021	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
Fiscal Year End: December 31	FY-A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																	
Net loss	(20.3)	(23.8)	(1.7)	(5.5)	(2.1)	(4.3)	(13.6)	(3.8)	(1.9)	(2.3)	(2.2)	(10.1)	(2.5)	(2.0)	(1.9)	(1.6)	(8.
Net loss from discontinuing operations		0.0															
Adjustments:																	
Stock-based compensation expense	2.7	2.4	0.3	0.5	0.2	0.2	1.1	0.3	0.3			0.6					0.
Depreciation and amortization	0.7	0.7	0.18	0.1	0.15	0.1	0.6	0.15	0.1	0.15	0.1	0.6	0.14	0.1	0.14	0.1	0.
Fair value of warrants issued for services	0.2	0.7	0.6	0.2	(0.2)	0.1	0.7	0.0	0.0			0.0					0.
Fair value of common stock issued forsen	vices								0.0								
Change in fair value of warrant liability, n	et of iss	uance ce	(9.6)	0.9	(1.6)	0.1	(10.2)					0.0					0
Excess warrant fair value			6.5	0.0	0.0	0.0	6.5					0.0					0
Common stock issued for services and se	0.0	0.0				0.1	0.1										
Accretion of discount on note receivable	(0.0)	0.0															1
Impairment on note receivable	0.9	0.0															1
Common stock issued in litigation settlen	0.0	0.0															1
Forgiveness of indebtness income	0.0	(1.3)															
Loss on sale of business	0.0	0.0															
WC changes	0.0	0.0															
Accounts receivable	0.2	0.7	0.1	(0.0)	0.1	0.0	0.3	(0.3)	0.1	0.0	0.0	(0.2)	0.0	0.0	0.0	0.0	6
Operating lease liabilities, net	0.2	0.1		(0.0)	0.1	0.0	0.0	(0.0)	(0.1)	0.0	0.0	(0.2)	0.0	0.0	0.0	0.0	1
Prepaid expenses and other	(0.9)	0.1	0.1	0.3	0.3	0.2	0.8	0.1	(0.1)	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0
Deposits	(0.0)	(0.0)	0.1	0.0	0.0	(0.0)	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0
Accounts payable	0.1	0.5	0.1	(0.2)	0.2	0.6	0.7	0.4	(0.5)	0.0	0.0	(0.1)	0.0	0.0	0.0	0.0	0
Accrued expenses	1.1	(0.9)	0.0	0.0	0.0	0.4	0.4	0.1	(0.3)	0.0	0.0	(0.1)	0.0	0.0	0.0	0.0	0
Employee retention credit liability	1.1	(0.3)	0.0	1.2	0.0	0.0	1.2	0.1	(0.3)	0.0	0.0	(0.2)	0.0	0.0	0.0	0.0	
Contract liability	(0.5)	0.6	(0.1)	(0.3)	(0.0)	(0.2)	(0.6)	0.5	(0.8)			(0.3)					0
Deferred rent and lease incentive liabil	0.5	0.0	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)	(0.0)	0.0			0.0					0
Tenant improvement allowance	(0.5)	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0
Other liabilities	(0.5)	0.5	(0.0)	0.0	0.0	(0.1)	0.0	0.0	(0.0)	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0
Net cash used in operating activities	(15.7)	(19.6)	(3.5)	(2.9)	(2.8)	(0.1)	(11.9)	(2.5)	(3.0)	(2.1)	(2.0)	(9.6)	(2.3)	(1.9)	(1.7)	(1.5)	(7
vet cash used in operating activities	(15.7)	(19.0)	(3.5)	(2.9)	(2.6)	(2.7)	(11.9)	(2.5)	(3.0)	(2.1)	(2.0)	(9.0)	(2.3)	(1.9)	(1.7)	(1.5)	1
Investing Activities																	1
Purchase of property and equipment	(2.4)	(0.9)	(0.2)	(0.2)	(0.2)	(0.2)	(0.8)	(0.2)	(0.1)	(0.1)	(0.1)	(0.3)	(0.1)	(0.1)	(0.1)	(0.1)	(0
	(2.4)	(0.9)		0.0	0.0	0.0		(0.2)	(0.1)	(0.1)	(0.1)	0.0	(0.1)	(0.1)	(0.1)	(0.1)	
Payment for asset purchase	(0.2)	0.0	(0.1)	0.0	0.0	0.0	(0.1)					0.0					
Cash acquired from acquisition																	0
Principal collections under note receivable	0.0	0.0	(0.2)	(0.0)	(0.2)	(0.0)	(0.0)	(0.2)	10.41	(0.4)	10.41	0.0	(0.4)	(0.4)	(0.4)	10.43	-
Net cash used in investing activities	(2.6)	(0.9)	(0.3)	(0.2)	(0.2)	(0.2)	(0.9)	(0.2)	(0.1)	(0.1)	(0.1)	(0.3)	(0.1)	(0.1)	(0.1)	(0.1)	(0.
																	1
Financing Activities																	1
Proceeds from sale of common stock, ne		0.0				0.0	0.0		7.5	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0
Proceeds from placement of common sto	ck and	prefund	8.0	0.0	0.0	4.0	12.0	3.9	0.0			3.9					0
Series A Preferred Stock redemption pay	(1.5)	0.0					0.0					0.0					0
Payments for issuance costs	(2.2)	0.0	(0.6)	0.0	0.0	(0.4)	(1.1)	(0.3)	(0.1)			(0.4)					0
Principal payments on debt	(0.0)	0.0					0.0					0.0					0
Proceeds from issuance of preferred stoc	0.0	0.0					0.0					0.0					0
	0.0	0.0					0.0					0.0					0
Proceeds from issuance of debt				0.0	0.0	3.6	10.9	3.6	7.4	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0
	24.2	0.0	7.4	0.0	0.0	5.0											
Proceeds from issuance of debt Net cash provided by financing activities Net cash increase (decrease)	24.2 5.8	0.0	7.4	(3.1)	(3.0)	0.7	(1.9)	1.0	4.3	(2.2)	(2.1)	1.1	(2.4)	(1.9)	(1.8)	(1.6)	(7
Net cash provided by financing activities								1.0 1.6	4.3 2.6	<mark>(2.2)</mark> 6.9	<mark>(2.1)</mark> 4.7	1.1 1.6				(1.6) (3.4)	(7. 2

Source: Company reports, Ascendiant Capital Markets estimates



ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.



Vivos Therapeutics, Inc.

 Ascendiant Capital Markets, LLC has not received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any



jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, consumer attitudes towards Sleep Apnea treatment options, changing macroeconomic factors, investor sentiment for investing in healthcare stocks, and changes in consumer or government priorities for healthcare.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ratings Distribution and Investment Banking Disclosure (As of July 12, 2024)

				Banking Services L2 Months
	Count	Percent	Count	Percent
Buy	58	98%	21	36%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	59	100%	21	36%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDA, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.



Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ, and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.